Lung Cancer, Nonsmall Cell Clinical Trials

11 recruiting

Lung Cancer, Nonsmall Cell Trials at a Glance

11 actively recruiting trials for lung cancer, nonsmall cell are listed on ClinicalTrialsFinder across 6 cities in 8 countries. The largest study group is Phase 2 with 4 trials, with the heaviest enrollment activity in Guangzhou, Beijing, and Bengbu. Lead sponsors running lung cancer, nonsmall cell studies include Aline Fusco Fares, MD, Cofactor Genomics, Inc., and Abramson Cancer Center at Penn Medicine.

Browse lung cancer, nonsmall cell trials by phase

Treatments under study

About Lung Cancer, Nonsmall Cell Clinical Trials

Looking for clinical trials for Lung Cancer, Nonsmall Cell? There are currently 11 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Lung Cancer, Nonsmall Cell trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Lung Cancer, Nonsmall Cell clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 111 of 11 trials

Recruiting
Phase 2

ctDNA-MRD Guided Consolidation Toripalimab in Stage IB-IIIA NSCLC

Lung Cancer, Nonsmall Cell
Sun Yat-sen University80 enrolled1 locationNCT06426511
Recruiting

Prospective Data Collection Initiative on Thoracic Malignancies

Lung CancerThoracic CancerThymus Cancer+5 more
Dutch Society of Physicians for Pulmonology and Tuberculosis12,000 enrolled10 locationsNCT06996249
Recruiting
Phase 1Phase 2

Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy

Lung Cancer, Nonsmall Cell
Abramson Cancer Center at Penn Medicine28 enrolled1 locationNCT04691817
Recruiting
Not Applicable

Immunonutrition for Improving the Efficacy of Immunotherapy in Patients With Metastatic Non-small Cell Lung Cancer

Lung Cancer, Nonsmall Cell
Fondazione IRCCS Policlinico San Matteo di Pavia180 enrolled1 locationNCT05384873
Recruiting

A Multicenter Cancer Biospecimen Collection Study

Cancer of Head and NeckLung Cancer, Nonsmall Cell
Cofactor Genomics, Inc.1,650 enrolled1 locationNCT04510129
Recruiting
Phase 2

Efficacy Analysis of Neoadjuvant Treatment in Lung Cancer Using Low-dose Nivolumab Combined With Chemotherapy

Lung Cancer, Nonsmall Cell
Aline Fusco Fares, MD33 enrolled1 locationNCT06667154
Recruiting
Not Applicable

Study of PRO in Patients with Advanced Pancreatic or Biliary Tract Cancer (BetterEveryDay)

Pancreatic CancerLung Cancer, Nonsmall Cell
Inna Chen, MD274 enrolled1 locationNCT04611867
Recruiting

Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy in ICIs Treated NSCLC Patients

Lung NeoplasmsLung Cancer, Nonsmall CellAdenocarcinoma of Lung+1 more
Geneplus-Beijing Co. Ltd.250 enrolled1 locationNCT04566432
Recruiting
Not Applicable

Understanding and Overcoming the Early Adaptive Resistance to EGFR Tyrosine-kinase Inhibitors in Lung Cancer Patients

Lung Cancer, Nonsmall Cell
University Hospital, Toulouse80 enrolled1 locationNCT04222335
Recruiting
Phase 3

A Randomised Open-label Phase III Trial of REduced Frequency Pembrolizumab immuNothErapy for First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC)

Lung Cancer, Nonsmall Cell
Imperial College London1,750 enrolled37 locationsNCT05085028
Recruiting
Phase 1Phase 2

A Phase I/II Clinical Study of SAF-189s in Non-small Cell Lung Cancer (NSCLC) Patients

Advanced Solid TumorAdvanced CancerLung Cancer, Nonsmall Cell
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.280 enrolled41 locationsNCT04237805